Here’s why Kazia Therapeutics and CLINUVEL were trending on the ASX today

Summary

  • Oncology focused drug development firm Kazia Therapeutics has commenced Phase 2 clinical trial of its investigational new drug, paxalisib.
  • CLINUVEL has enrolled the first acute arterial ischaemic stroke (AIS) patient for the treatment with afamelanotide in the CUV801 trial.

Two ASX healthcare shares, Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) and CLINUVEL Pharmaceuticals Ltd (ASX:CUV), updated the market with announcements related to patient enrolment in their clinical studies.

Oncology player Kazia Therapeutics enrolled the first patient in paxilisib study. CLINUVEL updated that its drug afamelanotide was administered to the first patient suffering from an acute arterial ischaemic stroke (AIS).

On 7 June 2021, ASX 200 closed lower, down 0.19%. However, some healthcare shares ended the day on a positive note, including Medlab Clinical Limited (ASX:MDC), Oneview Healthcare PLC (ASX:ONE), ECS Botanics Holdings Ltd (ASX:ECS) and Medibio Limited (ASX:MEB).

ALSO READ: ASX snaps 3-day gain as big banks weigh; Altium jumps 40%

Let us now discuss the updates of Kazia Therapeutics and CLINUVEL in detail-

First patient enrolled in Kazia’s paxilisib study

Oncology-focused drug development firm Kazia Therapeutics updated the market that the Phase 2 clinical trial of its investigational new drug, paxalisib, had been initiated. In addition, the Company stated that the first patient had been enrolled for the study.

Kazia revealed that this study was being performed at Dana-Farber Cancer Institute (DFCI) for the treatment of primary CNS lymphoma (PCNSL). DFCI is a Massachusetts-based world-leading cancer treatment and research centre.

ALSO READ: Kazia Therapeutics (ASX:KZA) begins recruitment for GBM AGILE study

Copyright © 2021 Kalkine Media

Lymphoma is a cancer of white blood cells and occurs in the lymphatic system. Besides, primary CNS lymphoma (PCNSL) occurs exclusively in the brain and CNS (central nervous system). Paxalisib belongs to the PI3K inhibitor class of drug that is well-validated in lymphoma outside the brain.

The study conducted at DFCI is an open-label Phase 2 clinical trial of paxalisib for the treatment of PCNSL and is expected to recruit up to 25 patients. The study is projected to complete in two years.

Furthermore, the Company will offer support, including study drug and a financial grant.

Dr James Garner, CEO of Kazia, commented-

On 7 June 2021, KZA shares last traded at AU$1.250, down by 1.575%.

CLINUVEL enrolled the first patient in Phase 2 CUV801 study

CLINUVEL revealed that its drug afamelanotide had been administered to the first patient suffering from an acute arterial ischaemic stroke (AIS) enrolled in the CUV801 trial.

CLINUVEL disclosed that, in total, six adult AIS patients would be evaluated in the Phase 2 CUV801 clinical trial. The study aims to evaluate the safety and therapeutic potential of afamelanotide in patients who are not qualified for standard stroke therapy.

Source: © Nastyazhi | Megapixl.com

The Company disclosed that the CUV801 study assesses the use of afamelanotide in six patients who have experienced an acute stroke. The main focus of the study will be monitoring safety following drug administration as the patients are admitted to the hospital.

ALSO READ: CLINUVEL develops its DNA repair program; to evaluate SCENESSE® in XP-V

Dr Pilar Bilbao, CLINUVEL Clinical Operations Manager, said-

On 7 June 2021, CUV shares closed at AU$27.95, down by 2.851%.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK